Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Plus Therapeutics (PSTV) Shares Outstanding (2016 - 2025)

Plus Therapeutics (PSTV) has disclosed Shares Outstanding for 7 consecutive years, with $131.9 million as the latest value for Q3 2025.

  • On a quarterly basis, Shares Outstanding rose 2042.47% to $131.9 million in Q3 2025 year-over-year; TTM through Sep 2025 was $131.9 million, a 2042.47% increase, with the full-year FY2024 number at $1952.0, changed 0.0% from a year prior.
  • Shares Outstanding was $131.9 million for Q3 2025 at Plus Therapeutics, up from $92.4 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $131.9 million in Q3 2025 to a low of $1952.0 in Q2 2021.
  • A 5-year average of $15.5 million and a median of $2.3 million in 2022 define the central range for Shares Outstanding.
  • Peak YoY movement for Shares Outstanding: skyrocketed 1137073.92% in 2022, then crashed 13338.99% in 2024.
  • Plus Therapeutics' Shares Outstanding stood at $1952.0 in 2021, then changed by 0.0% to $1952.0 in 2022, then changed by 0.0% to $1952.0 in 2023, then skyrocketed by 315205.23% to $6.2 million in 2024, then surged by 2042.47% to $131.9 million in 2025.
  • Per Business Quant, the three most recent readings for PSTV's Shares Outstanding are $131.9 million (Q3 2025), $92.4 million (Q2 2025), and $17.3 million (Q1 2025).